Reporting on ageing biology, longevity therapeutics and what the research actually supports — written by practising clinicians.
Inflammation is simultaneously the most over-claimed concept in consumer wellness and one of the best-supported in ageing biology. The way to hold both is to stop asking whether inflammation matters and start asking what is producing it in the patient in front of you.
By the time a patient raises an injection, they have usually decided they want one. The useful conversation is not whether to inject but what they are choosing between, and what each option can honestly be expected to do.
Buying a prescription medicine online can be entirely legitimate. It can also mean receiving an unapproved substance from a seller you cannot identify, with no one to call when something goes wrong. The difference is not obvious from the website.
Most people are told what a GLP-1 does to appetite and very little else. Several of the other changes matter more, and a few of them are worth knowing before you start rather than after.
Weight loss has always cost lean tissue. The current concern is legitimate, but it is usually stated in a way that both overstates the problem and obscures who is actually at risk.
The result arrives as a number against a reference range, which implies a precision the test does not have. Reading it properly means knowing four things the report will not tell you.
A patient sends a link and asks what you think. There is always a study. The useful question is what kind it is, and this literature fails in a small number of recurring, recognisable ways.
A patient returns at six months. The panel looks better, the epigenetic age reading has dropped two years, and they feel exactly as they did before. Something has changed. Whether anything has improved is a different question.
Selection for this class is mostly a question of exclusion. The diagnosis that would justify treatment is narrower than most patients asking for it realise, and the pharmacology creates a paradox that makes the selection question harder than it first appears.
Patients rarely ask how a peptide works. They ask whether it is safe. The honest answer is usually "it depends which one," and that answer only sounds evasive if you cannot explain why.
Longevity medicine is strongest when scientific rigour, clinical judgement and individual goals are brought together. Its objective is not to promise immortality or to treat ageing with an indiscriminate collection of products.
Ageing is not one process. It is a network of cellular changes that gradually reduces resilience, repair and function, and the hallmarks framework exists to make that network legible.
Regenerative medicine seeks to restore the biological capacity for repair rather than simply compensate for lost function. It is best understood not as one treatment but as a coordinated platform connecting biology, engineering, manufacturing and individualised clinical care.
The capacity of cells to maintain, repair and renew themselves depends on several interconnected systems. No single intervention activates all of them, which is why sequence matters more than the number of therapies applied.
Lifespan measures time. Healthspan measures the usable portion of it. Extending the first without protecting the second increases the years lived with disease and dependency.
Ageing tissues produce proportionally fewer long RNA transcripts and more short ones. The pattern holds across organs, cell types and species, and the mechanism behind it is now reasonably well understood.
BPC-157 has one of the largest preclinical literatures of any compound in this field and no published randomised controlled trial in humans for any indication. Both halves of that sentence are true, and the gap between them is the whole story.
These three compounds are routinely discussed as a single category. They act at different receptors, produce different signal patterns, and occupy different legal positions. The differences matter more than the similarity.
A peptide hormone changes what a cell does without ever entering it. Understanding how that works explains most of what is otherwise puzzling about peptide therapeutics.
By the time a patient raises peptides with you, they have usually been researching for months and may already be injecting. The conversation that follows determines whether you find out.
Most physicians finished training without ever encountering peptides as a therapeutic class. That was a reasonable curriculum decision when it was made. It is no longer one.
Peptides and proteins are built from the same amino acids. The distinction between them is partly conventional, but it determines how these molecules behave in the body, how they are manufactured, and which regulatory framework governs them.
Exosomes are a real biological mechanism with a large preclinical literature. The published human evidence is far smaller than the direct-to-consumer market suggests, and no product is FDA approved.
